NodThera touts po­ten­tial weight loss ef­fect of NL­RP3 in­hibitors

NodThera is mov­ing its NL­RP3 in­hibitors in­to the clin­ic af­ter pre­clin­i­cal da­ta showed it re­versed obe­si­ty and in­flam­ma­tion in mice in a study that com­pared it against No­vo Nordisk’s We­govy.

In the tri­al, mice re­ceiv­ing NT-0796, NodThera’s lead can­di­date, lost 19% of their start­ing body weight by 28 days — com­pa­ra­ble to mice who took semaglu­tide, which lost 21.5% of weight over the same time pe­ri­od.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER